Patient-reported outcomes in schizophrenia patients treated with once-monthly extended-release risperidone in a long-term clinical study

PURPOSE: RBP-7000 (PERSERIS™) is a once-monthly subcutaneous extended-release risperidone formulation approved by the United States Food and Drug Administration for the treatment of schizophrenia in adults. The objective of this study was to describe the long-term impact of RBP-7000 on health-relate...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Patient Prefer Adherence
Main Authors: Dhanda, Rahul, Varghese, Della, Nadipelli, Vijay R, Fava, Maurizio, Joshi, Namita, Solem, Caitlyn T, Graham, James A, Learned, Susan M, Heidbreder, Christian
Formato: Artigo
Idioma:Inglês
Publicado em: Dove 2019
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6612993/
https://ncbi.nlm.nih.gov/pubmed/31308636
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PPA.S202173
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados